1stOncology™: Cancer Intelligence Service – Page 15468 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

argenx to receive third preclinical milestone payment from collaboration with LEO Pharma

On April 12, 2018 argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, reported the achievement of its third preclinical milestone from its collaboration with LEO Pharma, following the approval of the clinical trial application (CTA) filing for ARGX-112 (Press release, argenx, APR 12, 2018, View Source [SID1234525279]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

"This milestone showcases the productivity of our collaboration with LEO Pharma, marking the final step before ARGX-112 may enter clinical development. It triggers the third of three success-based preclinical milestone payments under this collaboration. We are convinced of the potential of ARGX-112 to address unmet needs in inflammatory skin diseases and are excited to see the program approved for clinical development," commented Tim Van Hauwermeiren, CEO at argenx.

In May 2015, argenx entered into a research collaboration and exclusive license option agreement with LEO Pharma to develop and commercialize ARGX-112, a novel antibody discovered by argenx using its SIMPLE Antibody technology. During the collaboration term, argenx successfully concluded all ARGX-112 research and development activities required for the first filing by LEO Pharma of a CTA.

As part of the agreement, argenx has granted LEO Pharma an exclusive option to obtain a worldwide, exclusive license to the ARGX-112 program, to develop and commercialize licensed products for inflammatory skin disorders. In addition to the upfront and preclinical milestone payments, argenx may receive further regulatory and clinical milestone payments up to approximately €100mm as well as royalties on net sales of any product.

Alexion to Report First Quarter 2018 Results on Thursday, April 26, 2018

On April 12, 2018 Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) reported that the Company will report its financial results for the first quarter ended March 31, 2018 on Thursday, April 26, 2018 before the US financial markets open (Press release, Alexion, APR 12, 2018, View Source [SID1234525278]). Following the release of the financial results, Alexion management will conduct a conference call and audio webcast on Thursday, April 26, 2018, at 10:00 a.m. Eastern Time (ET).

To participate in this conference call, dial 888-394-8218 (USA) or 323-701-0225 (International), passcode 1013806 shortly before 10:00 a.m. ET. A replay of the call will be available from 1:00 p.m. ET through a limited time thereafter. The replay number is 888-203-1112 (USA) or 719-457-0820 (International), passcode 1013806. The audio webcast can be accessed on the Investor page of View Source

ERYTECH to Present Results from Phase I Trial of eryaspase in ALL and New Pre-clinical Data at AACR 2018

On April 12, 2018 ERYTECH Pharma (Euronext Paris: ERYP—Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, reported that it will present full results from its U.S. Phase I trial evaluating eryaspase (GRASPA) in combination with chemotherapy for the treatment of acute lymphoblastic leukemia (ALL) and pre-clinical data on the erymethionase program at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, being held April 14-18, 2018 in Chicago, Illinois (Press release, ERYtech Pharma, APR 12, 2018, View Source [SID1234525277]).

The U.S. Phase I ALL data will be presented during the poster session of the Phase I clinical trials by the lead author of the abstract, Dr. Alison Walker. The data from the dose-escalating Phase I clinical study demonstrate that eryaspase, L-asparaginase encapsulated in red blood cells, was well-tolerated when combined with CALGB 8811 protocol for frontline treatment of adults with ALL. Based on the PK data and the safety findings, the recommended dose for further clinical development is determined at 100 U/kg.

ERYTECH will also present pre-clinical data on the combination of eryaspase and erymethionase, methionine-gamma-lyase encapsulated in red blood cells, at a poster session on Wednesday, April 18, which show promising in vitro and in vivo bi-therapy therapeutic efficacy in different cancer models.

Poster Session: A Phase I study of eryaspase (L-asparaginase encapsulated in red blood cells) in combination with induction and consolidation chemotherapy for adult patients with newly diagnosed acute lymphoblastic leukemia (ALL)

Poster: #CT023 / 16
Lead Author:Dr. Alison Walker
Poster Session/Section: PO.CT01 – Phase I Clinical Trials 1
Date: Sunday, April 15
Time: 1:00 p.m. – 5:00 p.m.
Poster Session: Enzymatic combination investigation in cancer therapy

Poster: #5827 / 23
Lead Author Karine Aguera
Poster Session/Section: PO.ET01.04 – Combination Chemotherapy 2
Date: Wednesday, April 18
Time: 8:00 AM – 12:00 PM
Abstracts are available on the AACR (Free AACR Whitepaper) website. The two posters are to be presented at the 2018 AACR (Free AACR Whitepaper) Annual Meeting and will be available on the Erytech website after April 18, 2018.

New Preclinical Data Highlighting Eleven Biotherapeutics’ DeBouganin Program to be Presented at 2018 AACR Annual Meeting

On April 12, 2018 Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a late-stage clinical company developing next-generation antibody-drug conjugate (ADC) therapies for the treatment of cancer, reported that preclinical data from the company’s novel, next-generation ADC program using an innovative deBouganin cytotoxic protein payload will be presented during two poster sessions at the 2018 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting (Press release, Eleven Biotherapeutics, APR 12, 2018, View Source [SID1234525276]). The meeting is taking place April 14-18, 2018 in Chicago.

"We have uniquely designed our deBouganin payload to address tumor indications that can only be reached through systemic delivery. Our data show that deBouganin exhibits certain advantages over first-generation ADCs, which use more conventional small molecule cytotoxins, with respect to cell killing power, including the ability to kill cancer stem cells, circumvent multi-drug resistance and avoid cross-resistance mechanisms," said Gregory P. Adams, Ph.D., chief scientific officer of Eleven Biotherapeutics. "We are pleased to be presenting these promising data highlighting the potential activity and differentiation of our approach compared to first-generation ADCs."

DeBouganin is a proprietary de-immunized variant of bouganin, a ribosome inactivating protein that when internalized blocks protein synthesis, thereby leading to cell death. Eleven Biotherapeutics will present data from its VB6-845d program, a next-generation ADC comprised of a Fab fragment specific for the epithelial cell adhesion molecule (EpCAM) genetically linked to deBouganin via a furin protease sensitive peptide. Data being presented suggest that VB6-845d mediates tumor cell killing by an immunogenic cell death (ICD) pathway. The potential cross-priming effect initiated by VB6-845d-induced ICD suggests that VB6-845d in combination with immune checkpoint inhibitors may enhance their effectiveness in EpCAM-positive epithelial cancers.

Poster Title: VB6-845d Tumor Cell Killing Elicits Biologic Features of Immunogenic Cell Death
Date and Time:April 16, 2018 from 1:00 to 5:00 p.m. CT

In addition, in collaboration with Crescendo Biologics, the company will present data demonstrating that a fusion protein comprised of the company’s deBouganin payload and Crescendo’s Humabody are expressible as a soluble protein in E. coli supernatant. Crescendo’s Humabody products are a novel class of small, robust and potent protein therapeutics based on fully human VH domain building blocks. In vitro data support the potential of Humabody-deBouganin fusion constructs as anti-cancer therapeutics.

Poster Title: Engineering and Characterization of Anti-PSMA Humabody-DeBouganin Fusion Proteins

Date and Time:April 18, 2018 from 8:00 a.m. to 12:00 p.m. C

Personalized Tumor Drug Susceptibility Testing Platform by Percans Oncology

On April 11, 2018 Percans Oncology reported that it has developed i-CR, a personalized drug susceptibility testing platform for the precise treatment of colon cancer, to provide clinicians and patients with the most valuable medical plan for reference (Press release, Cothera Bioscience, APR 11, 2018, View Source [SID1234618854]).

Features of i-CR in vitro drug susceptibility testing platform

i-CR drug susceptibility testing technology focuses on the functionality of tumor cells. It investigates the response of tumor cells under the action of drugs instead of exploring the relationship between drug susceptibility and changes in genes and proteins. The i-CR results are more practical and correspondence to clinical outcomes. This technology takes small samples of patients’ tumors, and performs rapid and high-throughput, drug susceptibility tests for drugs that have been marketed or entered clinical trials, thus providing a strong basis for clinicians to make optmized medical plans for each individual patient.

Target Patients

l Patients newly diagnosed as stage III or IV colorectal cancer;

l Patients who have failed the standard first-line treatment plan and hope to choose the best plan;

l Patients who have local or distant metastases and cannot benefit from genetic testing;

l Patients who are resistant to targeted drugs and need to find effective multiple targeted drugs and targeted combinations.